文献速递白血病淋巴瘤

CXCR4拮抗剂破坏白血病-脑膜细胞黏附并减轻化疗耐药

CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance.
PubMed 文献 · Br J Haematol · 2022-12-19

本研究探讨CXCR4/CXCL12趋化因子轴在急性淋巴细胞白血病中枢神经系统白血病生态位中的作用,发现该轴参与白血病-脑膜细胞黏附,临床在研的CXCR4拮抗剂可破坏黏附、减轻共培养中的化疗耐药,并在体内增强阿糖胞苷靶向脑膜白血病细胞的疗效。

要点

  • CXCR4/CXCL12轴参与白血病-脑膜细胞黏附。
  • CXCR4拮抗剂可破坏白血病-脑膜细胞黏附。
  • CXCR4拮抗剂在体内增强阿糖胞苷靶向脑膜白血病细胞的疗效。

核心结论

  • CXCR4/CXCL12轴是中枢神经系统白血病生态位内细胞间相互作用的重要调节因子。
  • 支持进一步测试CXCR4拮抗剂克服中枢神经系统生态位介导的化疗耐药的疗效。

研究设计与样本

  • 研究采用白血病-脑膜细胞共培养实验及体内实验,评估CXCR4拮抗剂对白血病-脑膜细胞黏附和化疗耐药的影响。

主要发现

  • CXCR4/CXCL12趋化因子轴参与白血病-脑膜细胞黏附。
  • 临床在研的CXCR4拮抗剂可能穿过血脑屏障和血脑脊液屏障并穿透中枢神经系统,有效破坏白血病-脑膜细胞黏附。
  • 在白血病-脑膜细胞共培养实验中,CXCR4拮抗剂通过破坏细胞间相互作用减轻白血病化疗耐药。
  • 在体内,CXCR4拮抗剂增强阿糖胞苷靶向脑膜白血病细胞的疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The effective prophylaxis and treatment of central nervous system (CNS) involvement in acute lymphoblastic leukaemia (ALL) remains a significant clinical challenge. Developing novel and more effective CNS-directed therapies has been hampered, in part, by our limited understanding of the leukaemia niche in the CNS relative to the bone marrow. Accordingly, defining the molecular and cellular components critical for the establishment and maintenance of the CNS leukaemia niche may lead to new therapeutic opportunities. In prior work we showed that direct intercellular interactions between leukaemia and meningeal cells enhance leukaemia chemoresistance in the CNS. Herein, we show that the CXCR4/CXCL12 chemokine axis contributes to leukaemia-meningeal cell adhesion. Importantly, clinically tested CXCR4 antagonists, which are likely to cross the blood-brain and blood-cerebral spinal fluid barriers and penetrate the CNS, effectively disrupted leukaemia-meningeal cell adhesion. Moreover, by disrupting these intercellular interactions, CXCR4 antagonists attenuated leukaemia chemoresistance in leukaemia-meningeal cell co-culture experiments and enhanced the efficacy of cytarabine in targeting leukaemia cells in the meninges in vivo. This work identifies the CXCR4/CXCL12 axis as an important regulator of intercellular interactions within the CNS leukaemia niche and supports further testing of the therapeutic efficacy of CXCR4 antagonists in overcoming CNS niche-mediated chemoresistance.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jonart LM, Ostergaard J, Brooks A, et al. CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance. Br J Haematol. 2022. PMID: 36535585. doi:10.1111/bjh.18607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。